FY2027 Earnings Estimate for XENE Issued By William Blair

Key Points

• William Blair's analyst M. Minter estimates that Xenon Pharmaceuticals will report earnings of ($5.55) per share for FY2027, with an "Outperform" rating on the stock.
• The consensus estimate for Xenon Pharmaceuticals' current full-year earnings stands at ($3.10) per share, indicating a significant projected decline in earnings.
• Xenon Pharmaceuticals' stock experienced a 2.0% increase, opening at $36.70, while the stock has a market cap of $2.82 billion.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities research analysts at William Blair issued their FY2027 earnings per share estimates for shares of Xenon Pharmaceuticals in a report issued on Tuesday, August 12th. William Blair analyst M. Minter expects that the biopharmaceutical company will earn ($5.55) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same period last year, the firm earned ($0.75) earnings per share.

A number of other equities analysts have also recently weighed in on XENE. Wall Street Zen cut Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Needham & Company LLC lowered their target price on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Wedbush boosted their price target on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 12th. Evercore ISI initiated coverage on Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price target for the company. Finally, Royal Bank Of Canada decreased their price target on Xenon Pharmaceuticals from $57.00 to $55.00 and set an "outperform" rating for the company in a research note on Tuesday, August 12th. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $53.20.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE traded down $0.41 on Wednesday, hitting $37.82. The company's stock had a trading volume of 1,220,837 shares, compared to its average volume of 901,240. The company has a market capitalization of $2.92 billion, a PE ratio of -10.65 and a beta of 1.16. Xenon Pharmaceuticals has a 1 year low of $26.74 and a 1 year high of $46.00. The company has a 50-day simple moving average of $32.59 and a 200 day simple moving average of $33.97.

Institutional Trading of Xenon Pharmaceuticals

Several large investors have recently modified their holdings of the company. Farther Finance Advisors LLC bought a new stake in Xenon Pharmaceuticals during the second quarter valued at about $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Xenon Pharmaceuticals in the first quarter worth about $30,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Xenon Pharmaceuticals in the second quarter worth about $32,000. GF Fund Management CO. LTD. purchased a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth about $63,000. Finally, Quarry LP purchased a new stake in Xenon Pharmaceuticals during the fourth quarter valued at approximately $78,000. Institutional investors own 95.45% of the company's stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.